Evidence map›Paper›PMID 39698899›Full record

ArticleOncoimmunology2025

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.

Carmen G Cañizo, Félix Guerrero-Ramos, Mercedes Perez Escavy, Iris Lodewijk, Cristian Suárez-Cabrera, Lucía Morales, Sandra P Nunes, Ester Munera-Maravilla, Carolina Rubio, Rebeca Sánchez and 10 more

Abstract read
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Expression of PD-1 and PD-L1 in BCG-treated NMIBC.Bladder cancer (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Carmen G CañizoUrology Department, University Hospital '12 de Octubre', Madrid, Spain.
Félix Guerrero-RamosUrology Department, University Hospital '12 de Octubre', Madrid, Spain.
Mercedes Perez EscavyMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Iris LodewijkMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Cristian Suárez-CabreraMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Lucía MoralesMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Sandra P NunesMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Ester Munera-MaravillaMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Carolina RubioMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Rebeca SánchezCell Technology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Marta Rodriguez-IzquierdoUrology Department, University Hospital '12 de Octubre', Madrid, Spain.
Jaime Martínez de VillarrealCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
Francisco X RealCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
Daniel CastellanoOncology Department, University Hospital '12 de Octubre', Madrid, Spain.
Cristina Martín-ArriscadoScientific Support Unit, Research Institute I+12, University Hospital 12 de Octubre, Madrid, Spain.
David Lora PablosScientific Support Unit, Research Institute I+12, University Hospital 12 de Octubre, Madrid, Spain.
Alfredo Rodríguez AntolínUrology Department, University Hospital '12 de Octubre', Madrid, Spain.
Marta DueñasMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.
Jesús M ParamioMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.ORCID 0000-0001-7520-3177
Victor G MartínezMolecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.ORCID 0000-0002-5515-0626

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk non-muscle-invasive bladder cancer (NMIBC) presents high recurrence and progression rates. Despite the use of Bacillus Calmette-Guérin gold-standard immunotherapy and the recent irruption of anti-PD-1/PD-L1 drugs, we are missing a comprehensive understanding of the tumor microenvironment (TME) that may help us find biomarkers associated to treatment outcome. Here, we prospectively analyzed TME composition and PD-L1 expression of tumor and non-tumoral tissue biopsies from 73 NMIBC patients and used scRNA-seq, transcriptomic cohorts and tissue micro-array to validate the prognostic value of cell types of interest. Compared to non-tumoral tissue, NMIBC presented microvascular alterations, increased cancer-associated fibroblast (CAF) and myofibroblast (myoCAF) presence, and varied immune cell distribution, such as increased macrophage infiltration. Heterogeneous PD-L1 expression was observed across subsets, with macrophages showing the highest expression levels, but cancer cells as the primary potential anti-PD-L1 binding targets. Unbiased analysis revealed that myoCAF and M2-like macrophages are specifically enriched in high-grade NMIBC tumors. The topological distribution of these two cell types changed as NMIBC progresses, as shown by immunofluorescence. Only myoCAFs were associated with higher rates of progression and recurrence in three independent cohorts (888 total patients), reaching prediction values comparable to transcriptomic classes, which we further validated using tissue micro-array. Our study provides a roadmap to establish the landscape of the NMIBC TME, highlighting myoCAFs as potential prognostic markers.

Indexed as

B7-H1 AntigenBiomarkers, TumorMyofibroblastsTumor MicroenvironmentUrinary Bladder NeoplasmsAgedAged, 80 and overCancer-Associated FibroblastsFemaleHumansMacrophagesMaleMiddle AgedPrognosisProspective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanBladder cancercancer-associated fibroblastsMyofibroblastsPD-L1tumor microenvironment

Identifiers

PMID39698899
PMCPMC11660370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.